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BACKGROUND AND PURPOSE
The N-terminus of calcitonin gene-related peptide (CGRP) is important for receptor activation, especially the
disulphide-bonded ring (residues 1–7). However, the roles of individual amino acids within this region have not been
examined and so the molecular determinants of agonism are unknown. This study has examined the role of residues 1, 3–6
and 8–9, excluding Cys-2 and Cys-7.
EXPERIMENTAL APPROACH
CGRP derivatives were substituted with either cysteine or alanine; further residues were introduced at position 6. Their affinity
was measured by radioligand binding and their efficacy by measuring cAMP production in SK-N-MC cells and β-arrestin 2
translocation in CHO-K1 cells at the CGRP receptor.
KEY RESULTS
Substitution of Ala-5 by cysteine reduced affinity 270-fold and reduced efficacy for production of cAMP in SK-N-MCs. Potency
at β-arrestin translocation was reduced by ninefold. Substitution of Thr-6 by cysteine destroyed all measurable efficacy of both
cAMP and β-arrestin responses; substitution with either alanine or serine impaired potency. Substitutions at positions 1, 4, 8
and 9 resulted in approximately 10-fold reductions in potency at both responses. Similar observations were made at a second
CGRP-activated receptor, the AMY1(a) receptor.
CONCLUSIONS AND IMPLICATIONS
Ala-5 and Thr-6 are key determinants of agonist activity for CGRP. Ala-5 is also very important for receptor binding. Residues
outside of the 1–7 ring also contribute to agonist activity.
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Introduction
Calcitonin gene-related peptide (CGRP) is a 37 amino acid
peptide, which in humans and rodents is found in two forms:
α and β. It is an abundant neuropeptide that is widely dis-
tributed throughout the sensory nervous system. It is an
extremely potent vasodilator, which is involved in neurogenic
inflammation. CGRP receptor antagonists reduce migraine
pain in clinical trials (Recober and Russo, 2009). CGRP forms
a family with calcitonin (CT), adrenomedullin (AM), AM
2/intermedin, amylin and calcitonin receptor-stimulating
peptide (CRSP) (Takei et al., 2004; Katafuchi et al., 2009).
These peptides act on the CT or CT receptor-like receptors
(CLRs), which are family B GPCRs (receptor nomenclature
follows Alexander et al., 2013). CLR in complex with the
accessory protein receptor activity-modifying protein 1
(RAMP1) gives the CGRP receptor, whereas CLR with RAMP2
or 3 gives AM1 and AM2 receptors (receptor nomenclature
follows Alexander et al., 2013; Supporting Information
Table S1). The CT receptor complexes with RAMPs to give the
AMY1, AMY2 and AMY3 receptors for amylin (McLatchie et al.,
1998; Christopoulos et al., 1999; Muff et al., 1999); these exist
as either (a) or (b) forms depending on the splice variant of
CT receptor that is involved (Poyner et al., 2002). CGRP is a
potent agonist at the AMY1(a) receptor (Hay et al., 2005; Bailey
et al., 2012).
The binding of CGRP to the CGRP receptor follows the
typical pattern established for peptide ligands to family B
GPCRs in that the C-terminus of the peptide binds to the
extracellular domain of CLR (in association with the extra-
cellular domain of RAMP1), whereas the N-terminus interacts
with the transmembrane (TM) domain of CLR and its associ-
ated extracellular loops. It has been suggested that all the
peptide ligands for family B GPCRs share a common motif at
their N-termini: a helix cap or an activation loop (Neumann
et al., 2008; Watkins et al., 2012). In the case of the CT/CGRP
family, the motif is formed by a disulphide-bonded ring; in
CGRP this involves cysteines at positions 2 and 7. Truncation
of the disulphide-bonded loop gives the antagonist, CGRP8–37,
showing that residues 1–7 are required for receptor activation
and N-terminal fragments of CGRP are reported to have
agonist activity (Chiba et al., 1989; Maggi et al., 1990).
There has been some work on the structure–activity rela-
tionship for the C-terminus of CGRP acting on the CGRP
receptor (Conner et al., 2002; Lang et al., 2006), but much less
is known about the N-terminus of the peptide when it acti-
vates this receptor or the AMY1 receptor (Watkins et al.,
2013). The importance of the disulphide bond has been
established (Dennis et al., 1989; Saha et al., 1998), and there
are a few studies based mainly on deletions (Thiebaud et al.,
1991; Hakala et al., 1994; Heino et al., 1998). It is possible to
extend the N-terminus of CGRP, as with [Tyr0]-CGRP, while
retaining high affinity (Dennis et al., 1989) although efficacy
may be compromised (Poyner et al., 1992). The details of how
CGRP interacts with the TM and extracellular loop regions of
its receptor(s) remain obscure (Barwell et al., 2011b).
Although there is little experimental evidence for the role
of individual amino acids at the N-terminus of CGRP, com-
parison of naturally occurring peptide sequences is informa-
tive. Position 1 of CGRP is not fully conserved and can either
be serine or alanine (Supporting Information Fig. S1). Posi-
tion 3 is usually asparagine, although in human α and mar-
moset CGRP, it is aspartate. Thereafter, there is a very high
degree of sequence identity up to position 14 in species from
mammals to bony fish, emphasizing the conservation at the
N-terminus of CGRP. Comparing CGRP with other members
of the CT family of peptides including examples of the primi-
tive cartilaginous and jawless fish (Supporting Information
Fig. S2; see also Wong and Takei, 2009; Takei et al., 2010), the
most striking feature is the conservation of position 6 in
peptides apart from equine CGRP-1 [actually the equine
equivalent of CRSP (Ogoshi et al., 2006)], CRSP 2 and 3 and
AM4 in Takifugu rubripes and Tetraodon nigroviridis. AM4 has
only been described in bony fish and in other species the
threonine is retained. The equivalent of positions 1 and 5 is
group conserved as small hydrophobic amino acids (glycine,
alanine and serine). There is extensive conservation of resi-
dues 1–9 between CGRP and amylin from all species.
In this study, we investigated the structure–activity rela-
tionship of the N-terminus of CGRP, using amino acid sub-
stitutions of residues 1, 3–6 and 8–9, on CGRP receptor
binding, production of cAMP and β-arrestin 2 translocation.
These positions were substituted with either alanine or
cysteine. Cysteine and alanine are small hydrophobic amino
acids that are often group conserved along with serine in
proteins. The results indicate that Ala-5 and Thr-6 are impor-
tant determinants of CGRP activity at the CGRP receptor.
Methods
Peptides
All peptides are derivatives of human α CGRP, containing a
Cys-2-Cys-7 disulphide bond and C-terminal amide. CGRP
was purchased from American Peptide (Sunnyvale, CA, USA)
or Bachem (St Helens, Merseyside, UK). [Cys1]-, [Cys6]-, [Cys8]-
and [Cys9]-CGRP were synthesized by Alta Biosciences, Bir-
mingham, UK. [Cys3]-, [Ala4]-, [Cys5]-, [Ala6]-, [Ser6]-, [Asp6]-,
[Lys6]-, [Ala8]- and [Ala9]-CGRP peptides were synthesized by
solid phase peptide synthesis at the University of Auckland
using the Fmoc/tBu method on a 0.1 mmol scale. Briefly, Rink
amide aminomethyl resin was prepared as described (Harris
et al., 2011), and the peptide elongated using a CEM micro-
wave peptide synthesizer (CEM Corporation, Matthews, NC,
USA) as previously described (Harris et al., 2008). For [Cys3]-
and [Cys5]-CGRP peptides, the non-disulphide cysteines were
protected as the trifluoroacetic acid-stable tert-butyl ethers.
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For the other cysteine-substituted peptides, the non-
disulphide cysteines were protected as acetamidomethyl
derivatives. The peptides were cleaved from the resin with
concomitant removal of side chain protecting groups with
94.0% trifluoroacetic acid, 1.0% triisopropylsilane, 2.5%
water and 2.5% ethanedithiol (v/v/v/v) for 2–3 h, precipi-
tated with cold diethyl ether, isolated by centrifugation, dis-
solved in 50% aqueous acetonitrile containing 0.1%
trifluoroacetic acid and lyophilized. The crude peptides were
dissolved in 0.1 M Tris (pH = 8.3) at a concentration of
1 mg·mL−1 and the oxidation (disulphide formation) allowed
to proceed at room temperature open to air. Monitoring by
reverse phase HPLC indicated that the reaction was typically
complete after 12 h. The crude product was lyophilized, redis-
solved in 50.0% aqueous acetonitrile containing 0.1% trif-
luoroacetic acid and purified by semi-preparative reverse
phase HPLC using a C18 Gemini (Phenomenex, Torrance,
CA, USA) column (10 × 250 mm) at a flow rate of 5 mL·min−1
and eluted using an appropriate gradient based on the ana-
lytical HPLC profile. Fractions containing the pure peptide
were identified by electrospray mass spectrometry and/or
HPLC, pooled and lyophilized. All peptides were >95% purity
as judged by integration of the HPLC chromatogram at
210 nm, and peptide masses were confirmed by electrospray
mass spectrometry. For [Cys3]- and [Cys5]-CGRP peptides, fol-
lowing the oxidation, the crude peptide was recovered by
solid phase extraction and lyophilized. To remove the tert-
butyl on the cysteine at [Cys3] or [Cys5], the peptide was then
dissolved in trifluoroacetic acid : anisole (9:1, v/v) at a con-
centration of 15 mg·mL−1, cooled to 0°C and trifluoroacetic
acid : trifluoromethanesulphonic acid (4:1, v/v) (0.4 mL) was
added. The solution was stood at 0°C for 3 min, poured into
cold ether and recovered by centrifugation. Purification as
described earlier afforded the pure peptides in >95% purity.
Cell culture and transfection
SK-N-MC cells were grown in DMEM/F12 medium supple-
mented with 10% fetal calf serum as described previously
(Poyner et al., 1998). Cos 7 cells were grown in DMEM/10%
FBS and were transfected with human HA-tagged CT (a)
receptors and human myc-tagged RAMP1 using polyethylen-
imine and identical methods to those described previously
for the CGRP receptor (Bailey and Hay, 2006). In this case, the
transfection gives an AMY1(a) receptor. This protocol has been
successfully used to express these receptors (Qi et al., 2008).
This protocol was also used to express the CGRP receptor in
Cos 7 where appropriate.
Measurement of cAMP
Production of cAMP in SK-N-MC cells for all analogues except
[Cys5]-hαCGRP was by a radioreceptor assay, as described
previously (Poyner et al., 1998). Cells were treated with
increasing concentrations of the CGRP analogues for approxi-
mately 10 min. Where antagonist activity was being assessed,
the cells were pretreated with peptides for 10 min prior to the
addition of the CGRP derivative (Poyner et al., 1998). For
[Cys5]-hαCGRP, a different clone of SK-N-MC cells was used
and cAMP production was measured via AlphaScreen (Perkin
Elmer, Wellesley, MA, USA), as described previously (Gingell
et al., 2010). This assay was also used to investigate the action
of all derivatives at the AMY1(a) receptor and other experi-
ments using Cos 7 cells. In control experiments to confirm
cross-compatibility of the two SK-N-MC cell clones using
AlphaScreen, [Ala4]-hαCGRP and [Ala6]-hαCGRP gave similar
reductions in pEC50 values as seen when this parameter was
measured by a radioreceptor assay with the other clone of
cells (values of 7.58 ± 0.43 and 7.39 ± 0.16 vs. 9.00 ± 0.33 for
CGRP, n = 3–4; compare with Table 1).
β-Arrestin translocation
Translocation of β-arrestin after a 2 h stimulation with pep-
tides was measured using a DiscoveRx ‘PathHunter eXpress
β-arrestin’ kit (93-0446E; Birmingham, West Midlands, UK),
with CHO-K1 cells expressing the human CGRP receptor and
β-arrestin 2. The role of β-arrestin 2 in CGRP receptor desen-
sitization has been previously demonstrated (Hilairet et al.,
2001; Padilla et al., 2007).
Radioligand binding
The ability of peptides to displace 125I-CGRP binding
to SK-N-MC cell membranes was measured in a
microcentrifugation-based binding assay, as described previ-
ously (Poyner et al., 1998).
Data analysis
GraphPad Prism 5.00 or 6.00 (GraphPad Software Inc., San
Diego, CA, USA) was used for data fitting. Concentration–
response curves were fitted to a sigmoidal function with Hill
slope constrained to unity to obtain pEC50 and maximum
responses (Emax) values. Displacement curves were analysed to
obtain pIC50 values. Schild plots were fitted by linear regres-
sion to obtain slope and intercepts. pEC50 and pIC50 values
were compared with that of human αCGRP using Dunnett’s
test with either a normal or repeated measures one-way
ANOVA, as appropriate. To assess if Emax values differed from
wild type, 95% confidence limits were calculated using Stu-
dent’s t-statistic.
Materials
[125I]-iodohistidyl8 human α CGRP (125I-CGRP) and [3H]-cAMP
were purchased from Perkin Elmer (Wellesley, MA, USA).
Other reagents were as described previously (Barwell et al.,
2011a). The SK-N-MC cells were from the European Collec-
tion of Animal Cell Cultures (Porton Down, UK), except those
used for examining [Cys5]-CGRP, which were a gift from Dr
Fiona Marshall (Heptares, Stevenage, UK) (used for radioli-
gand binding) or from American Type Culture Collection
(used for cAMP measurements). Cells were changed due to
problems with the old batch losing expression of CGRP recep-
tors over passages, as has been documented previously
(Choksi et al., 2002).
Results
The role of the side chains of positions 1, 3,
4, 8 and 9 at CGRP receptors
As expected, CGRP was a potent agonist at stimulating cAMP
production in SK-N-MC cells (Figure 1; Table 1), with a pEC50
BJPStructure–activity relationship for CGRP
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within the considerable range reported in the literature
(Poyner et al., 1998; Howitt et al., 2003); it also displaced
125I-CGRP with a Ki that was 30-fold less than its pEC50
(Figure 3; Table 1). It was a very potent agonist at stimulating
β-arrestin 2 translocation in CHO-K1 cells (Figure 4; Table 1).
As can be seen in Table 1 and Figures 2 and 3, the intro-
duction of a cysteine to replace aspartate in native CGRP at
position 3 made little difference to potency on cAMP
although there was a small (approximately sixfold) decrease
in affinity. Substitution of alanine by cysteine at position 1
caused around a 10-fold decrease in potency on cAMP and
modest reduction in Emax; these changes were accompanied
by a sixfold decrease in affinity. Substitution of Thr-4, Val-8
and Thr-9 in native CGRP by alanine caused 6- to 10-fold
decreases in potency on cAMP; there were no significant
changes in affinity.
The analogues were also examined for their activity at
stimulating β-arrestin 2 translocation in CHO-K1 cells
(Figures 4 and 5; Table 1). They all showed a reduced potency
of 3- to 10-fold, which was significant for every analogue
except [Ala8]-CGRP. Apart from [Cys3], they also all showed
decreased Emax; for [Ala8]-CGRP the reduction in maximum
was 20%, but for the other analogues it was approximately
40%.
Figure 1
Effects of CGRP alanine and Thr-6 analogues on cAMP production in SK-N-MC cells. Values are means ± SEM, n = 3–6 and are normalized to the
response seen with CGRP.
Figure 2
Effects of CGRP cysteine analogues on cAMP production in SK-N-MC cells. Values are means ± SEM, n = 3–6 and are normalized to the response
seen with CGRP.
BJPStructure–activity relationship for CGRP
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The role of the side chains of positions
5 and 6
Substitution of Ala-5 in native CGRP by cysteine caused over
a 270-fold decrease in affinity. There was a ninefold decrease
in potency for stimulation of β-arrestin 2 translocation, and
the Emax was reduced by 45% compared with CGRP. The
analogue was a partial agonist at stimulating cAMP produc-
tion in SK-N-MC cells. A measureable response was only
found in cells where the pEC50 for CGRPwas over 9, indicating
tight coupling to Gs activation. In these cells, the Emax was
reduced by almost 70%, and the potency was decreased over
100-fold (Table 1; Figures 2, 3 and 5). Consistent with its low
efficacy, it could antagonize the action of CGRP. The slope of
the resulting Schild plot was not significantly different from
unity (1.33 ± 0.30), resulting in a pKb estimate for [Cys5]-CGRP
of 7.74 ± 0.12 (Figure 6C). This is in good agreement with the
pKi of 8.00 ± 0.26 (Table 1). By comparison, in the same series
of experiments, CGRP8–37, the best characterized CGRP
antagonist, had a pKb of 9.42 ± 0.12 (n = 4, data not shown).
Although this is rather high, considerable variations in affin-
ity for this antagonist are sometimes seen (Hay et al., 2008).
Substitution of Thr-6 in native CGRP by either alanine or
serine caused substantial decreases in potency in cAMP pro-
duction; the potency for [Ser6]-CGRP was reduced over
10-fold and for [Ala6]-CGRP there was almost a 100-fold
reduction in potency with a trend towards a reduced Emax.
There were reductions in affinity that was the largest for
[Ala6]-CGRP (30-fold). There were also decreases in potency
when β-arrestin 2 translocation was examined and both the
Figure 3
Inhibition of [125I]-CGRP binding by CGRP analogues in SK-N-MC cell membranes. Values are means ± SEM, n = 3–6.
Figure 4
Stimulation of β-arrestin 2 translocation by CGRP alanine and Thr-6 analogues in CHO-K1 cells. Values are means ± SEM, n = 3 and are normalized
to the response seen with CGRP.
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analogues were partial agonists, with the Emax to [Ser6]-CGRP
reduced by 40% and that to [Ala6]-CGRP by almost 60%
(Figure 4; Table 1).
Substitution of Thr-6 by cysteine, aspartate and lysine had
more profound effects. [Asp6]- and [Lys6]-CGRP both had over
100-fold decreases in affinity. They also failed to stimulate
cAMP production or β-arrestin 2 translocation at concentra-
tions of up to either 1 μM (β-arrestin 2) or 10 μM (cAMP). The
loss of efficacy was confirmed by examining the cAMP
response to CGRP in the presence of 10 μM of either of these
agents. Both produced small but significant rightward shifts
in the concentration–response curves to CGRP with no sup-
pression of the Emax (Figure 6A): pEC50 for CGRP, 8.66 ± 0.19;
with 10 μM [Asp6]-CGRP, 8.04 ± 0.04 (P < 0.05) and with
10 μM [Lys6]-CGRP, 8.11 ± 0.09 (P < 0.01), indicating that
they were acting as competitive antagonists. For [Cys6]-CGRP,
the loss in affinity was only fivefold (Figure 3; Table 1), but as
with the aspartate and lysine derivatives, it was also unable to
stimulate either production of cAMP or translocation of
β-arrestin 2. To confirm the loss of efficacy at cAMP produc-
tion, the analogue was used as an antagonist to shift the
concentration–response curve to CGRP (Figure 6B); the
Schild plot had a straight line with a slope not significantly
different from unity (0.98 ± 0.20) and a pA2 of 8.08 ± 0.13
(n = 3). This indicates that it behaves as a competitive
antagonist.
Actions of analogues at stimulating cAMP
production at the AMY1(a) receptor
The structure–activity relationship with the analogues at the
CGRP receptor was also broadly apparent when the deriva-
tives were used to stimulate cAMP production in Cos 7 cells
via the AMY1(a) receptor (Table 2; Figures 7 and 8), which uses
the CT receptor rather than CLR. [Cys5]-CGRP was 75-fold
less potent than CGRP and was a partial agonist. In Cos 7 cells
transfected with CLR and RAMP1 (Figure 7), [Cys5]-CGRP
appeared as a full agonist (Emax 90 ± 8% of that of CGRP) albeit
Figure 5
Stimulation of β-arrestin 2 translocation by CGRP cysteine analogues in CHO-K1 cells. Values are means ± SEM, n = 3 and are normalized to the
response seen with CGRP.
Table 2
Actions of CGRP analogues on AMY1(a) receptor-stimulated cAMP
production in Cos 7 cells
pEC50 Emax (% CGRP)
Control CGRP analogue CGRP analogue
[Cys3] 9.22 ± 0.13 8.90 ± 0.03 108 ± 4
[Ala4] 9.22 ± 0.13 8.57 ± 0.22* 161 ± 45
[Cys5] 9.66 ± 0.15 7.78 ± 0.12*** 50 ± 4***
[Ala6] 9.76 ± 0.15 7.00 ± 0.44** 42 ± 11**
[Cys6] – Undetectable
[Ser6] 9.76 ± 0.15 9.25 ± 0.03 76 ± 19
[Asp6] – Undetectable
[Lys6] – Undetectable
[Ala8] 9.22 ± 0.13 8.97 ± 0.07 143 ± 11
[Ala9] 9.22 ± 0.13 8.21 ± 0.32** 89 ± 9
Values are means ± SEM, n = 3–6. *,**,***, P < 0.05, 0.01, 0.001
compared with CGRP, Dunnett’s test followed by one-way ANOVA
or Student’s t-test, as appropriate.
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much less potent than CGRP itself (pEC50 for CGRP, 9.66 ±
0.22; pEC50 for [Cys5]-CGRP, 7.90 ± 0.20). [Ala9]-hαCGRP was
10-fold less potent than CGRP. [Ala6]-CGRP was over 700-fold
less potent than CGRP and it was also a partial agonist. There
were no consistent stimulations of cAMP production seen
with [Cys6]-, [Asp6]- or [Lys6]-CGRP. The potency of [Ser6]-
CGRP was not significantly different from that of CGRP, and
although there was a trend for a reduced Emax, this did not
reach significance and [Ala8]-CGRP also behaved like CGRP.
Discussion
This paper assesses the contribution of the first nine residues
of CGRP, excluding the cysteines at positions 2 and 7 to
receptor binding and activation. The results highlight the
contribution of residues in the middle and C-terminal por-
tions of this part of CGRP, especially Ala-5 and Thr-6.
Substitution of the alanine at position 5 by cysteine
causes large decreases in affinity and efficacy at cAMP pro-
duction in SK-N-MC cells (Figure 8). The affinity loss is large,
especially considering that there is only around a 10-fold loss
typically found for deletion of the first seven amino acids to
give CGRP8–37 (Chiba et al., 1989; Watkins et al., 2013). It
seems that the sulfhydryl group at position 5 results in the
N-terminus adopting a conformation that impairs the
binding of the rest of the CGRP molecule. In CHO-K1 cells,
the reduction in efficacy seen with [Cys5]-CGRP at stimulat-
ing β-arrestin translocation is smaller than that seen on cAMP
in SK-N-MC cells, although this may simply reflect the better
receptor coupling seen in the former cells, as discussed below.
Substitution of Thr-6 by cysteine gave only a modest
reduction in affinity, but all measurable efficacy was lost for
coupling to both Gs and translocation of β-arrestin 2. Threo-
nine is able to take part in both hydrogen bonds and hydro-
phobic interactions, and the structure–activity relationship
revealed in this study suggests that both are likely to be
important. The failure of serine to substitute for threonine at
CGRP is striking as the position of the hydroxyl group in the
two analogues is identical; they differ only in that threonine
has an extra methyl group on the β-carbon. However, these
data are consistent with the fact that serine is not found in
position 6 in any known native member of the CT/CGRP
family (Supporting Information Figs S1 and S2). It would
appear likely that the threonine fits into a tightly constrained
pocket, where both the methyl and the hydroxyl groups are
important. The probability is that the hydroxyl group is
involved in a hydrogen bond; the methyl group may pack
against a hydrophobic group. The poor binding and lack of
efficacy seen with both the lysine and aspartate derivatives
may imply that the partner for threonine is uncharged;
however, it is also possible that steric hindrance could explain
the large effects with these derivatives.
Throughout the CT/CGRP family, positions 5 and 6 are
highly conserved, suggesting that they may have similarly
important roles across all members of the family. The equiva-
lent of position 5 is group conserved as a small hydrophobic
(or weakly hydrophilic) residue: alanine, serine or glycine,
except for AM4 sequences where larger hydrophobic residues
are present. The equivalent of position 6 is always a threonine
except in AM4 and CRSP 2 and 3, and there is some doubt
whether these three peptides are agonists at CLR-based recep-
tors. Porcine CRSP 2 and 3 do not stimulate cAMP production
at CLR or CT receptor expressed in Cos 7 cells, with or
without RAMPs (Katafuchi et al., 2009), and dog CRSP 2 has
no action on the CT receptor of LLC-PK cells (Ogoshi et al.,
2006). There is no information on the biological activity of
AM4, although as the mRNA is present in large amounts in
the skin of Takifugu, it has been suggested that it may have an
antimicrobial role (Ogoshi et al., 2003).
There is no previous work on position 5 of CGRP, but one
study has looked at position 6. [Val6]-CGRP was inactive at
stimulating cAMP production in porcine iris ciliary body
(Heino et al., 1998), in agreement with the conclusions from
this study that the residue cannot be substituted without loss
of activity. Interestingly, an AM derivative, where replace-
Figure 6
Antagonism of cAMP production by CGRP with (A) [Asp6] and [Lys6]-
and (B) [Cys6]-CGRP, (C) [Cys5]-CGRP in SK-N-MC cells.
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ment of the equivalent of Thr-6 (Thr-20) was reported to
reduce potency on blood pressure (Kuwasako et al., 2011), is
consistent with this being an important residue for all
members of the CT/CGRP family. Similarly, substitution of
Thr-6 in amylin by alanine resulted in reduced activity of the
peptide (Roth et al., 2008).
Substitution of the remaining residues of CGRP had gen-
erally rather modest but significant effects on binding and
potency at stimulating cAMP and β-arrestin 2 translocation.
There was a good correlation between the potency of the
analogues at stimulating cAMP and their binding affinities
(r2 = 0.78), although the correlation between binding and
β-arrestin translocation was much weaker (r2 = 0.40, Figure 8).
Asp-3 was the least significant substitution with cysteine only
causing a small reduction in affinity. A photoaffinity probe
can be accommodated here with retention of high affinity
Figure 7
Effects of CGRP analogues on cAMP production in AMY1(a) receptors in Cos 7 cells. A single experiment representative of 3–6 is shown. Each point
is the mean ± SEM of three or four determinations. Responses are normalized to the response seen with CGRP. For the final part of this figure,
the response of CGRP and [Cys5]-CGRP on the CGRP receptor transfected into these cells is shown alongside the AMY1(a) receptor data.
BJPStructure–activity relationship for CGRP
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binding (Stangl et al., 1993), consistent with the side chain of
the residue sitting in an exposed area when CGRP is bound to
its receptor, although it is highly conserved in CGRP as either
aspartate or asparagine. Substitutions at all the remaining
positions impaired the potency of the analogue at stimulat-
ing cAMP and efficacy at β-arrestin 2 translocation, indicating
that their side chains have roles in receptor activation. There
was little evidence for selective activation of either of the two
pathways with any of these analogues (Figure 8), although as
the responses were compared in different cell lines, quantita-
tive comparison of efficacy measures is difficult.
As CGRP8–37 is an antagonist, it is surprising that substi-
tutions at positions 8 and 9 apparently reduced efficacy.
However, a photoaffinity probe attached to position 8 of
salmon CT can label a residue at the top of the third extra-
cellular loop (Dong et al., 2004). Potentially, residues in this
part of the ligand could interact directly with the juxtamem-
brane part of the receptor and enhance the ability of the
disulphide-bonded ring to cause receptor activation. Thr-9
may, alternatively, act indirectly by helping to stabilize a
conformation of the N-terminus of CGRP that is favourable
for binding by making a hydrogen bond to connect with an
appropriate H-bond acceptor located between residues 1 and
7 on the disulphide-bonded ring. There is support for this
from NMR evidence (Breeze et al., 1991) and molecular
dynamics simulations (D. L. Rathbone and D. R. Poyner,
unpublished) as well as the position of this residue within the
N-cap proposed by Watkins et al. (2012). Whatever the
mechanism is, it is clear that agonist activity is influenced by
residues outside the disulphide-bonded loop. Interestingly,
CGRP1–7 is reported to be an antagonist (Dennis et al., 1989)
whereas CGRP1–12 can mimic the hypotensive effects of CGRP
and so may be an agonist (Maggi et al., 1990); this raises the
possibility that the 1–7 ring requires other residues such as
Val-8 and Thr-9 in order to activate the receptor.
The CGRP analogues showed a similar pattern of activity
for stimulation of cAMP production on the AMY1(a) receptor
as they did on the CGRP receptor (Figure 8D; r2 = 0.70); CGRP
is a potent agonist at both receptors (Hay et al., 2005). In
particular, Ala-5 and Thr-6 were both important for agonist
action. Potency was also influenced by substitution of Thr-9;
this is conserved between CGRP and amylin. Thus, the same
general determinants of receptor activity are likely to operate
at both receptors for coupling to Gs. A detailed comparison of
the importance of individual residues at stimulating the
AMY1(a) and the CGRP receptor is complicated by the fact that
the AMY1(a) receptor was expressed in Cos 7 cells and the
CGRP receptor was expressed in SK-N-MC cells. There seems
to be better coupling of the CGRP receptor to Gs in the Cos 7
cells compared with the SK-N-MC cells as [Cys5]-CGRP was a
full agonist in the former but not the latter. This could also
relate to relative expression levels of the receptors (endog-
enous vs. overexpressed).
Although it is not possible on the basis of the data in this
study to propose a model of how CGRP binds to its receptor,
a number of general points can be made. The first and third
extracellular loops of CLR play only relatively minor roles in
binding CGRP (Barwell et al., 2011a); the second extracellular
loop is much more significant (Barwell et al., 2012; Woolley
et al., 2013). We have previously modelled CGRP bound to
the TM domain of CLR, in close proximity to CLR (Woolley
et al., 2013). This model is consistent with the data in the
current study. The side chain of Ala-5 and the methyl group
of Thr-6 are buried in the interface between TM helices 5 and
Figure 8
Correlations between effects of CGRP analogues. (A) Binding v cAMP production, CGRP receptor; (B) beta-arrestin translocation v cAMP
production, CGRP receptor; (C) binding v beta-arrestin translocation, CGRP receptor; (D) cAMP production, AMY1(a) receptor v CGRP receptor.
Values are the Δlog pEC50, or Δlog pKi, where the value for the analogue was subtracted from that of its paired control. Thus, 1 represents a 10-fold
reduction, 2 represents a 100-fold reduction and 3 for 1000-fold. Where activity could not be detected no value is included.
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6; the hydroxyl group on Thr-6 could H-bond to a backbone
carbonyl on the C-terminal portion of the second extracellu-
lar loop. Asp-3 is in an unhindered position, free from steric
constraints. Ala-1 points between the top of the first extra-
cellular loop and TM helix 1, allowing N-terminal extensions
of the peptide. The residues that interact with CGRP in the
CLR as part of the CGRP receptor are likely to be conserved in
the CT receptor.
In conclusion, this paper provides new information on
the structural requirements needed for agonist activity of
CGRP. Alanine at position 5 and threonine at position 6 are
particularly important for receptor activation. CGRP posi-
tions 1, 4, 8 and 9 also influence agonist activity. It would be
interesting to evaluate analogues based on the pentapetide
CGRP5–9, as this may contain the key components needed for
receptor activation.
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